What are the treatment options for a patient with chronic eczema or psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tabla de Corticosteroides Tópicos por Potencia

Los corticosteroides tópicos se clasifican en 7 categorías según su potencia vasocontrictora, desde ultra-alta (Clase 1) hasta baja (Clases 6-7), y la selección debe basarse en la severidad de la enfermedad, localización anatómica y edad del paciente. 1

Clase 1: Ultra-Alta Potencia (Very Potent)

  • Betametasona dipropionato aumentado 0.05% (crema, ungüento, loción) 1
  • Clobetasol propionato 0.05% (crema, ungüento, loción, gel, espuma, champú) 1
  • Desoximetasona 0.25% (crema, ungüento) 1
  • Diflorasona diacetato aumentado 0.05% (crema, ungüento) 1
  • Fluocinonida 0.1% (crema) 1
  • Flurandrenolida 4 μg/cm² (cinta) 1
  • Halobetasol propionato 0.05% (crema, ungüento) 1

Clase 2: Alta Potencia (Potent)

  • Amcinonida 0.1% (crema, ungüento) 1
  • Betametasona dipropionato 0.05% (crema, ungüento) 1
  • Betametasona dipropionato aumentado 0.05% (loción) 1
  • Desoximetasona 0.25% (crema, ungüento) 1
  • Desoximetasona 0.05% (gel) 1
  • Diflorasona diacetato aumentado 0.05% (ungüento) 1
  • Diflorasona diacetato 0.05% (crema, ungüento) 1
  • Fluocinonida 0.05% (crema, ungüento, gel, solución) 1
  • Halcinonida 0.1% (crema, ungüento) 1
  • Mometasona furoato 0.1% (ungüento) 1
  • Triamcinolona acetonida 0.5% (crema, ungüento) 1

Clase 3: Potencia Media-Alta (Upper Mid-Strength)

  • Amcinonida 0.1% (crema, loción) 1
  • Betametasona dipropionato 0.05% (crema) 1
  • Betametasona valerato 0.1% (ungüento) 1
  • Betametasona valerato 0.12% (espuma) 1
  • Diflorasona diacetato 0.05% (crema) 1
  • Fluticasona propionato 0.005% (ungüento) 1
  • Triamcinolona acetonida 0.1% (ungüento) 1
  • Triamcinolona acetonida 0.5% (crema) 1

Clase 4: Potencia Media (Mid-Strength)

  • Betametasona valerato 0.12% (espuma) 1
  • Desoximetasona 0.05% (crema) 1
  • Fluocinolona acetonida 0.025% (ungüento) 1
  • Flurandrenolida 0.05% (ungüento) 1
  • Hidrocortisona valerato 0.2% (ungüento) 1
  • Mometasona furoato 0.1% (crema, loción) 1
  • Triamcinolona acetonida 0.1% (crema, loción) 1
  • Triamcinolona acetonida 0.2% (aerosol) 1

Clase 5: Potencia Media-Baja (Lower Mid-Strength)

  • Betametasona dipropionato 0.05% (loción) 1
  • Betametasona valerato 0.1% (crema, loción) 1
  • Clocortolona pivalato 0.1% (crema) 1
  • Fluocinolona acetonida 0.025% (crema) 1
  • Fluocinolona acetonida 0.01% (champú, aceite) 1
  • Fluticasona propionato 0.05% (crema, loción) 1
  • Flurandrenolida 0.05% (crema, loción) 1
  • Hidrocortisona butirato 0.1% (crema, ungüento, loción, solución) 1
  • Hidrocortisona probutato 0.1% (crema) 1
  • Hidrocortisona valerato 0.2% (crema) 1
  • Prednicarbato 0.1% (crema) 1
  • Triamcinolona acetonida 0.025% (ungüento) 1
  • Triamcinolona acetonida 0.01% (loción) 1

Clases 6-7: Baja Potencia (Low Potency)

  • Hidrocortisona 0.5-2.5% (crema, ungüento, loción) 1
  • Dexametasona 0.1% (crema) 1

Consideraciones Críticas de Seguridad

Los corticosteroides de Clase 1 (ultra-alta potencia) deben usarse con precaución por períodos limitados solamente, con duración máxima de 2-4 semanas continuas para prevenir atrofia cutánea, estrías, telangiectasias y absorción sistémica. 1, 2

Los corticosteroides de baja potencia deben usarse en cara, áreas intertriginosas y zonas susceptibles a atrofia por esteroides (como antebrazos). 1

La cantidad máxima de corticosteroides de ultra-alta potencia no debe exceder 50g por semana. 2

No se deben usar más de 100g de preparaciones de potencia moderada (Clase 3-4) por mes sin supervisión dermatológica. 1

El uso de preparaciones de Clase 1 o Clase 2 debe estar bajo supervisión dermatológica. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment Escalation for Psoriasis Unresponsive to Medium-Potency Corticosteroids

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended treatment with steroid cream for lymphedema dermatitis?
What is the recommended treatment for mild skin conditions using low potency corticosteroids (cortisone)?
What is the recommended treatment for mild skin conditions using low potency corticosteroids (corticoids)?
What is the potency of Celestoderm (betamethasone valerate) cream?
What is the best treatment for chronic eczema in the ears?
What supplements are recommended for a woman with endometriosis to alleviate symptoms?
What is the ideal time to initiate brain radiation therapy for a patient with residual meningioma (meningioma) after a status epilepticus partialis, who is now seizure-controlled with antiepileptic medications, such as levetiracetam (levetiracetam) or phenytoin (phenytoin), following a previous meningioma resection?
What is the diagnosis and management for a patient presenting with non-blanching red macules?
What are the recommendations for managing aggressive behavior in an elderly adult with dementia, currently on Macrobid (nitrofurantoin), who has exhibited violent outbursts, including physical attacks on caregivers?
What are the contraindications for using corticosteroids in a patient with chronic eczema or psoriasis, particularly those with a history of diabetes, hypertension, glaucoma, osteoporosis, or taking anticoagulant medications?
What is the appropriate diagnosis and treatment approach for a young adult patient presenting with symptoms of mononucleosis and non-blanching red macules?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.